Cann Group has appointed former Ipsen boss Peter Koetsier as its new CEO, starting next Monday (January 16).
Koetsier replaces Peter Crock, who announced he was stepping down as CEO in October 2022 after six years in the job.
Cann said Koetsier brings more than 30 years of experience in general management, marketing and commercial leadership roles with global pharmaceutical companies.
Most recently, he was Head of Asia Pacific for French biopharmaceutical company Ipsen, where he developed and led the implementation of a successful growth strategy including the commercial launch of new brands.
Previous roles include general manager of Australia/New Zealand with Ipsen and senior management positions with Astra/Zeneca UK, and Bristol-Myers Squibb in Europe.
Cann chairman Allan McCallum said: “Peter is an experienced pharma industry executive with an established track record of driving strong revenue growth in complex and changing environments.
“His experience and skills are ideally suited to the needs of Cann and to meeting the opportunities that continue to develop within the medicinal cannabis industry.”
Koetsier added: “I have a strong interest in new therapeutic areas and see tremendous potential for medicinal cannabis.
“Cann has established a genetics and production/manufacturing base that is world class. The opportunity now is to capitalise on those assets and drive profitable growth.”
Crock, who will be available to assist during the transition period, also welcomed the appointment.
Koetsier’s base salary is A$350,000 plus superannuation, options and performance-based incentives.
